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Host response  to viral infection may take many forms including  stimulation 
of humoral and cellular immune mechanisms and production of interferon. The 
importance of each of these mechanisms in individual viral infections has been 
the subject of several recent reviews (1-4). The role of cellular  immunity in 
vaccinia infection was first suggested by yon Pirquet in 1907 (5), and has been 
studied extensively in recent years (2, 6-9). Its role relative to those of antibody 
and interferon, however, remains unresolved (6-11). Many of the investigations 
concerning  host response in vaccinia infection have employed immunosuppres- 
sants in an attempt to isolate one or more reactive mechanisms for particular 
attention  (6,  8).  Among the most potent known suppressants of cellular  im- 
munity are anti-lymphoid sera (12).  Such sera have been used to study the 
relative role of cellular  responses  in several viral infections,  including  lympho- 
cytic choriomeningitis,  yellow fever, Rauscher leukemia,  Moloney leukemia, 
polyoma, herpes simplex, rabies, and influenza  (13-20). 
In  the  present report,  rabbit  anti-mouse  thymocyte (RAMT)  serum  was 
demonstrated to increase morbidity and mortality induced by vaccinia infec- 
tion in mice after intravenous virus administration.  However, it was found to 
have no effects on the course of primary or secondary infection after intra- 
cerebral inoculation. The suppressive effects of RAMT serum on host resistance 
to intravenously administered virus did not appear to be related to reduced 
interferon or antibody production, but rather to markedly diminished cellular 
immune responsiveness. 
Materials and Methods 
Miz.e.--Male ICR mice, 3-4 wk old, were used in all experiments. 
Viruses.--Vaccinia  virus (IHD-E neurotropic strain) was obtained from Dr. W. A. Cassel, 
Emory University. A 20% mouse brain suspension contained 107"° LDa0 per 0.03 ml. Vaccinia 
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virus titrations of the original inoculum and of infected organs were performed by intracerebral 
inoculation of 3-wk old ICR mice. Mengo virus in infected L  cell superuatant fluid was ob- 
tained from Dr. W. Ashe, Emory University. It contained 107"° plaque-forming units (PFU) 
per ml. 
Ant6-Thymocyte Sera.--RAMT serum was prepared as described by Levey and Medawar 
(12)  by immunizing rabbits with two intravenous inoculations of 109 dispersed viable ICR 
mouse thymus cells.  Individual sera were pooled  and  absorbed against erythrocytes. The 
effectiveness of the pool was assayed by its ability (a) to diminish peripheral blood lymphocyte 
counts by 50% within 4 hr after a single intraperitoneal inoculation of 0.3 ml and (b) to prevent 
clinical and histologic signs of LCM virus infection in ICR mice given three intraperitoneal 
inoculations (0.05 ml) of RAMT serum at 3-day intervals before virus challenge. This latter 
test has been found in our laboratory to be a reliable assay of suppression of cellular immunity 
(14). All RAMT and normal rabbit sera were shown to be free of anti-vaccinia activity by 
intracerebral virus neutralization assays in mice. 
TABLE  I 
Effects of Rabbit Anti-mouse  Tkyrnocyte (RAMT)  Serum  and Normal  Rabbit Serum  (NRS) 
on Primary Vaccinia Infection in Mice 
Virus dilution 
10t 
10-~ 
10-3 
10  4 
10-7 
lO-S 
Route of 
inoculation 
i.v° 
i.v. 
i.v. 
i.c. 
i.c. 
i.c. 
RAMT 
No. of mice 
20 
10 
10 
12 
12 
13 
Mortality 
% 
80 
50 
20 
100 
33 
15 
NRS 
No. of mice 
20 
10 
10 
12 
9 
10 
MortaliW 
% 
5 
0 
0 
100 
45 
0 
All animals received 0.3 ml of RAMT serum or NRS intraperitoneaUy on days  --6,  --3, 
0, +3, +6, and vaccinia virus on day 0. Intracerebral (i.c.)  virus doses were 0.03 ml; intra- 
venous (i.v.) doses were 0.05 ml. 
Experimental Design 
Primary Response.--148  mice were divided into two groups (Table I). One group was inoc- 
ulated with 0.3 ml of RAMT serum every 3rd day beginning 6 days before virus inoculation, 
and the other received normal rabbit serum (NRS)  according to the same schedule. On day 
zero, mice were inoculated either intravenously or intracerebrally with vaecinla virus. Intra- 
venous doses were 0.05 ml and dilutions in Hanks' medium were 10-1-10-~; intracerebral doses 
were 0.03 ml and dilutions were 10-6-10  -s. Animals were observed daily for signs of vaccinia 
infection, i.e., lethargy, dehydration, ataxla, ruffled fur; in addition intravenously inoculated 
mice were observed for development of tail lesions as described by Boyle et al. (21). Gross and 
light microscopic examinations and virus titrations were performed on organs from representa- 
tive animals of  each group.  Organs were fixed in buffered formalin, and 4-# sections were 
stained with hematoxylin and eosim 
Interferon analyses were performed on serum from 22 animals intravenously inoculated with 
vaecinia virus (10-1), according to a  modification of the plaque reduction technique of Glas- 
gow (10, 22). Serum samples collected 12 hr after virus] inoculation were acidified (pH 2) for 48 HIR$CH,  NAI~rMIAS~ MURPHY,  AND  KRAMER  123 
hr, brought back to neutrality,  and incubated overnight on L cell monolayers in prescription 
bottles.  100 PFU of Mengo virus per bottle were adsorbed to the cultures for 30 rain, and nu- 
trient agar overlay containing 200 #g/m1 of protamine sulfate was added. After 48 hr of incuba- 
tion, 1.0 ml neutral  red (1:1000) was added and plaques were counted. Per cent inhibition was 
plotted on arithmetic  probability  paper,  and  the reciprocal of the dilution  giving 50%  in- 
hibition was used to represent the units of interferon per unit volume of serum. 
Survivors of intravenous  virus inoculation were tested  by a microteehnique for vaccinia 
heanagglutination inhibition  (HI) antibodies 3 wk after initial viral challenge. These animals 
were subsequently rechallenged intracerebrally with 108 LD60 of vaccinia virus. 
Secondary Response.--136 mice were vaccinated twice by tail scarification with 106 LD60 
of vaccinia virus. I month after the second vaccination these mice were divided into two groups 
one which received RAMT serum (72 animals), the other NRS, according to the same dosage 
schedules as described under Primary response. On day zero the animals were challenged with 
103 to 106 LD60 intracerebraliy  (10-25 animals per dilution).  Mice were observed daily for 
signs of infection, and gross and light microscopic examinations were performed on organs 
from dying animals. Representative  animals from both groups were tested  for vaccinia HI 
antibodies I day before and 3 days after virus rechallenge (24 animals tested). 
RESULTS 
A. Primary Response 
Primary Response to Intravenous Admlnistration.--RAMT  serum  markedly 
altered the course of intravenous vaccinia infection,  resulting in an increased 
morbidity and mortality (Fig. 1). At a  10  -1 virus dilution,  20 %  of the RAMT 
serum-treated animals survived compared to 95 %  of the NRS  group; at 10  -3, 
50 %  of the RAMT serum group and 100 %  of the NRS group survived. Num- 
bers and size of tail lesions were also increased in RAMT serum-treated  ani- 
mals.  The number of pocks was approximately four times  greater  in RAMT 
serum-treated  animals  than in the NRS group (Table II), and the pock size 
was enlarged by approximately 50 %. 
Histologic  and  Virologic Observations.--Tail  lesions  were  composed  histo- 
logically  of acute  necrotizing  inflammatory  areas  with  accumulated  cellular 
debris  consisting  of degenerating  polymorphonuclear  leukocytes  and  plasma 
ceils (Fig. 3). In RAMT serum-treated animals these areas were larger and less 
well  circumscribed;  frequently  eosinophilic  cytoplasmic inclusions  and  inter- 
stitial  edema were present.  Overlying epidermis,  though generally intact,  was 
frequently hypertrophied in areas of dermal involvement. RAMT serum treat- 
ment also was associated with widespread virus multiplication and destruction 
in other organs. Both groups developed areas  of interstitial  necrotizing pneu- 
monitis (Fig. 4) with lung virus titers of 104--105 LD60 per 0.03 ml, whereas only 
RAMT serum-treated  mice had detectable virus and demonstrable lesions in 
other organs. "liters in the RAMT serum group ranged from 10  s.3 to 104"° LD~6 
per 0.03 ml in liver, spleen, and kidney, and necrotic foci were found in liver, 
meninges (Fig. 5), and brain parenchyma. Occasionally a necrotizing exudative 
mitral valvulitis was found in RAMT serum-treated  animals  (Fig. 6).  Spleen 
and lymph nodes of RAMT serum-treated  mice exhibited  depletion  of small 124  CELLULAR  IMMUNITY IN  VACCINIA INFECTION 
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Fro. 1.  Survival curves demonstrating effects of RAMT serum and NRS on mortality after 
intravenous administration of vaccinia virus in doses of 10-1-10  -~. 
TABLE II 
Effect  of RAMT  Serum  and  NRS  on  Tail  Pocks  Induced  by  Intravenous  Vaccinia  Virus 
Pretreatment*  No. of animals  Total pocks  Mean No. pocks 
RAMT, 10  -2 
NRS, 10  -* 
RAMT, 10  -8 
NRS, 10-3 
10 
8 
123 
21 
27 
5 
17.6 
4.2 
2.7 
0.6 
* All animals received 0.3  ml of either RAMT serum or NRS intraperitoneally on days 
--6, --3, 0, +3, +6; virus dilutions 10  -2 and 10  -* were given intravenously in  doses of 0.05 
ml on day 0. 
lymphocytes, a  change characteristically seen in RAMT  serum-treated  animals 
(13). 
Interferon  Measurements.--No  differences  were  found  among  animals  that 
received RAMT  serum,  NRS,  or no treatment  (22 animals  tested).  The mean 
titers in all three groups were between 20-25 units/ml. 
Serologic  Observations.--No  differences  were  found  in  levels  of vaccinia  HI HIRSCH, NAHMIAS, MURPHY, AND KRAMER  125 
antibody between the groups pretreated with either RAMT serum or NRS (16 
animals tested). Median titers in both groups were 1:64 with ranges from 1:16 
to 1:128. All animals were resistant to rechallenge with 10  s LDs0 of vaccinia 
virus administered intracerebrally. 
Primary Response to Intracerebral Administration.--Whereas  RAMT serum 
had marked effects after intravenous virus administration, it had no effect on 
the course of infection after intracerebral inoculation (Fig. 2). Both groups had 
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Fro. 2. Survival curves demonstrating effects of RAMT serum and NRS on mortality 
after intracerebral administration  of vaccinia  virus in doses  of 10-6-10  -8. 
severe necrotizing meningitis and encephalitis similar to that after primary in- 
travenous inoculation (Fig. S) with gliosis, neuronal degeneration, foamy cells, 
acute inflammatory cells, and occasional hemorrhages. Except for depletion of 
small lymphocytes in nodes and spleens of RAMT serum-treated animals, all 
other organs were normal in appearance in both groups. 
B. Secondary Response 
RAMT serum did not alter the course of infection in animals immunized with 
vaccinia virus by tail scarification and challenged intracerebrally. Mortality in 
both RAMT serum and NRS groups was equivalent at all virus concentrations 126  CELLULAR  TM3WT.TNITY  IN VACCINIA  INFECTION 
tested, even when 106 LDs0 of vaccinia virus was administered intracerebraUy. 
The total mortality was 32 % in the RAMT serum group (23/72) and 23 % in 
the NRS group (15/64); these differences are not significant at the 0.05 level by 
the chi-square test. On light microscopic histological examination severe necro- 
tizing meningitis and encephalitis were  demonstrated in  dying animals.  No 
significant differences were found in prechallenge HI antibody level or in post- 
challenge antibody response between RAMT- and NRS-treated groups or be- 
tween dying animals and survivors (24 animals tested). The average titers be- 
fore challenge in all groups were from 1:32  to 1:64 and after challenge from 
1:64 to 1:128. 
DISCUSSION 
The course of vaccinia infection in vivo depends on various factors including 
strain of virus  (23),  route of inoculation (24,  25),  species  of animal (2),  and 
status  of host defense mechanisms (2,  6-11).  Among host factors shown to 
participate in reactivity to this virus are circulating antibody (11, 26),  inter- 
feron  (6,  10),  and cell-mediated immune responses  (2,  4).  No unanimity of 
opinion has developed regarding the relative roles of the latter two mechanisms 
in responsiveness to vaccinia virus. 
Friedman et al. (6) found that guinea pigs in which skin hypersensitivity and 
antibody production were blocked by X-irradiation and methotrexate but in 
which the capacity to produce interferon was preserved recovered from vaccinia 
infection as rapidly as normal animals. These workers hypothesized that locally 
produced interferon was instrumental in recovery from infection. However, the 
guinea pig may not have been a good model because of its inherent resistance to 
vaccinia virus (2); in addition, absence of skin reactivity may not necessarily 
have reflected absence of cellular immunity since skin tests may be relatively 
insensitive assays of this response (7, 27). In contrast to the work of Friedman 
et al., Pincus and Flick reported a  series  of experiments that demonstrated a 
role for cellular immunity in primary responsiveness to vaccinia virus  (7-9). 
They found that (a) the ability of various inbred strains of rabbits to develop 
rapid and severe reactions to vaccinia was directly proportional to their ability 
to mount delayed hypersensitivity to other antigens, and (b)  techniques that 
inhibited the expression of cellular immunity, e.g.  inoculation of "anti-mono- 
nuclear" cell serum locally or the induction of neonatal immunologic unrespon- 
siveness,  inhibited the  primary vaccinia lesion.  The neonatally unresponsive 
rabbits frequently developed disseminated vaccinia after intradermal infection; 
autopsy findings in  these  animals were  similar  to  those described above  in 
RAMT serum-treated mice inoculated intravenously with vaccinia virus. 
In humans progressive vaccinia has been closely related to conditions asso- 
ciated with defects of cellular immunity, such as thymic dysgenesis or other less 
well-categorized deficiency syndromes  (3,  11,  28,  29).  Local inoculations  of HIRSCH, BIAHMIAS, MURPHY, AND  KRA.MER  127 
immune leukocytes have resulted in marked regression of such vaccinial lesions 
(11, 28). Although some workers have proposed that the observed effects may 
have been a result of interferon production by the transferred leukocytes (10), 
the balance of evidence suggests that the effects are mediated by cellular  im- 
munity. One patient so treated had her own leukocytes assayed for interferon 
production ability, and the response was adequate (28). Similarly, intact capaci- 
ties of leukocytes to produce interferon were found in a patient with vaccinia 
gangrenosa and deficient  cellular  immunity (29),  and in another with thymic 
dysgenesis (3). 
Suppression of cenular immunity is the primary action of anti-thymocyte 
serum, although  the mechanisms by which this is accomplished are not well 
understood (12). The present study indicates that RAMT serum did not affect 
the production of interferon in response to vaccinia virus infection.  As in other 
viral infections,  it also did not appear to suppress hemagglutination inhibition 
and  complement-fixing  antibody formation  (13,  14). Hence, its potentiating 
effect on primary intravenous virus infection must be ascribed to its cellular 
depressant capacity. This suppression,  whether on antigen-processing  cells or on 
sensitized  effector lymphocytes, allowed the virus to multiply not only in the 
lung, its apparent intravenous target organ, but also in the brain, liver, spleen, 
and skin.  Augmented virus multiplication,  in turn,  resulted in increased tail 
lesions and organ damage, as well as greater mortality. 
Intracerebral inoculation of vaccinia virus resulted in multiplication in the 
brain and in the development of severe necrotizing meningitis and encephalitis. 
Spread from the central nervous system to other organs did not appear to be 
important in the pathogensis after administration by this route, and the course 
did not appear  to be influenced  by suppression  of cell-mediated immunity. 
Similar differences between RAMT serum effects on the course of infection after 
peripheral and intracerebral virus inocnlations have been found in the case of 
herpes simplex virus (17). 
Secondary responsiveness  to intracerebral challenge was also not affected by 
RAMT serum pretreatment.  Two vaccinations by tail scarification  with vac- 
cinia virus provided protection of approximately 75 %  of the animals  against 
subsequent intracerebral rechallenge, whether the animals had received RAMT 
serum or not. These results indicate that cellular responsiveness  does not play a 
major role in secondary immunity after intracerebral challenge, although it may 
be a significant factor in response to challenge by other routes, such as the skin. 
It is probable that the presence of circulating antibody and possibly of inter- 
feron protected the majority of mice against fatal meningitis and encephalitis, 
since both antibody and interferon have ready access to infected brain (30, 31). 
In view of the increasing  use of anti-lymphoid sera in human tissue trans- 
plantation  (32), knowledge concerning  the effects of these sera on previously 
established viral immunity has become important practically (33). Our results 128  CELLULAR rMMUNITY IN VACCINIA INFECTION" 
suggest that although susceptibility to primary virus infection may be markedly 
increased by anti-lymphoid serum treatment, secondary immunity may not be 
so readily affected. Volkert and  Lundstedt,  however,  have  recently demon- 
strated that preestabhshed immunity to lymphocytic choriomeningitis virus can 
be abrogated by treatment with anti-lymphoid sera,  despite its inability to 
reduce complement-fixing antibody formation (15). These findings suggest that 
cell-mediated responsiveness can play the major part in secondary immunity to 
some viruses, and be relatively unimportant in immunity to others. The im- 
portance of anti-thymocyte serum in reducing established immunity to other 
common viruses such as varicella and measles remains to be determined. 
SI~MARY 
Rabbit anti-mouse thymocyte serum suppressed host cell-mediated respon- 
siveness to intravenously administered vaccinia virus, thereby augmenting the 
morbidity and mortality of this infection. It did not affect either humoral anti- 
body or interferon production in response to vaccinia virus. No effects were 
noted on primary or secondary immunity to intracerebral virus inoculation. 
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Sections stained with hematoxylin and eosin. 
FIG. 3. Section of tail from a mouse inoculated intraperitonedly with anti-thymo- 
cyte serum  and  intravenously with  vaccinia virus.  Dermal  necrosis and  acute  in- 
flammatory infiltrate.  X  500. 
FIG. 4. Lung from mouse inoculated intraperitoneally with anfi-thymocyte serum 
and intravenously with vaccinia virus. Focal coagulafive necrosis and cellular debris. 
X  150. 131 FIG.  5.  Meninges  from  mouse  inoculated  intraperitoneally with  anti-thymocyte serum  and  intra- 
venously with vaccinia virus. Acute inflammatory exudate, congestion, and necrosis. X  180. 
FIG.  6.  Mitral  valve from  mouse  inoculated  intraperitoneally with  anti-thymocyte serum  and in- 
travenously with  vaccinia virus. Inflammatory infiltrate of polymorphonuclear leukocytes and plasma 
cells as higher magnification made plain. X 500. 
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